EssilorLuxottica Société anonyme (ESLOY)
USD 139.97
(0.4%)
USD 139.97
(0.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.18 Billion EUR | 1.54% |
| 2022 | 6.1 Billion EUR | 27.14% |
| 2021 | 4.7 Billion EUR | 85.05% |
| 2020 | 2.6 Billion EUR | -31.7% |
| 2019 | 3.82 Billion EUR | 78.62% |
| 2018 | 2.62 Billion EUR | 25.84% |
| 2017 | 2.21 Billion EUR | 3.05% |
| 2016 | 1.64 Billion EUR | 1.23% |
| 2015 | 1.57 Billion EUR | 10.8% |
| 2014 | 1.67 Billion EUR | 28.33% |
| 2013 | 1.11 Billion EUR | 3.55% |
| 2012 | 1.09 Billion EUR | 20.35% |
| 2011 | 892.17 Million EUR | 5.28% |
| 2010 | 831.09 Million EUR | 9.13% |
| 2009 | 730.14 Million EUR | 14.93% |
| 2008 | 761.86 Million EUR | 2.43% |
| 2007 | 673.14 Million EUR | 11.02% |
| 2006 | 603.65 Million EUR | 12.37% |
| 2005 | 527.57 Million EUR | -1.86% |
| 2004 | 461.28 Million EUR | 7.44% |
| 2003 | 514.17 Million EUR | 2.8% |
| 2002 | 500.17 Million EUR | 9.54% |
| 2001 | 456.6 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.49 Billion EUR | 0.0% |
| 2024 Q1 | 1.49 Billion EUR | -47.51% |
| 2023 Q4 | 2.85 Billion EUR | 182.95% |
| 2023 FY | - EUR | 1.54% |
| 2023 Q1 | 1.41 Billion EUR | -52.43% |
| 2023 Q2 | 3.34 Billion EUR | 137.29% |
| 2023 Q3 | 1 Billion EUR | -69.85% |
| 2022 Q2 | 3.2 Billion EUR | 103.75% |
| 2022 FY | - EUR | 27.14% |
| 2022 Q1 | 1.57 Billion EUR | -40.59% |
| 2022 Q3 | 1 Billion EUR | -68.49% |
| 2022 Q4 | 2.96 Billion EUR | 193.71% |
| 2021 Q3 | 968.5 Million EUR | -58.11% |
| 2021 FY | - EUR | 85.05% |
| 2021 Q1 | 1.02 Billion EUR | -49.2% |
| 2021 Q2 | 2.31 Billion EUR | 126.33% |
| 2021 Q4 | 2.64 Billion EUR | 173.31% |
| 2020 FY | - EUR | -31.7% |
| 2020 Q1 | 293 Million EUR | -85.62% |
| 2020 Q2 | 857 Million EUR | 192.49% |
| 2020 Q3 | 719 Million EUR | -16.1% |
| 2020 Q4 | 2.01 Billion EUR | 179.69% |
| 2019 Q3 | 863.5 Million EUR | -60.24% |
| 2019 FY | - EUR | 78.62% |
| 2019 Q2 | 2.17 Billion EUR | 133.17% |
| 2019 Q1 | 931.5 Million EUR | 78.11% |
| 2019 Q4 | 2.03 Billion EUR | 136.02% |
| 2018 Q1 | 611 Million EUR | -9.28% |
| 2018 Q3 | 523 Million EUR | -14.4% |
| 2018 Q4 | 523 Million EUR | 0.0% |
| 2018 FY | - EUR | 25.84% |
| 2018 Q2 | 611 Million EUR | 0.0% |
| 2017 Q3 | 673.5 Million EUR | 55.36% |
| 2017 Q2 | 433.5 Million EUR | 0.0% |
| 2017 Q1 | 433.5 Million EUR | -0.34% |
| 2017 FY | - EUR | 3.05% |
| 2017 Q4 | 673.5 Million EUR | 0.0% |
| 2016 Q2 | 421.5 Million EUR | 0.0% |
| 2016 FY | - EUR | 1.23% |
| 2016 Q4 | 435 Million EUR | 0.0% |
| 2016 Q3 | 435 Million EUR | 3.2% |
| 2016 Q1 | 421.5 Million EUR | 5.51% |
| 2015 Q4 | 399.5 Million EUR | 0.0% |
| 2015 Q2 | 406.5 Million EUR | 0.0% |
| 2015 Q1 | 406.5 Million EUR | 2.78% |
| 2015 FY | - EUR | 10.8% |
| 2015 Q3 | 399.5 Million EUR | -1.72% |
| 2014 Q3 | 395.5 Million EUR | 48.41% |
| 2014 FY | - EUR | 28.33% |
| 2014 Q1 | 266.5 Million EUR | 0.0% |
| 2014 Q4 | 395.5 Million EUR | 0.0% |
| 2014 Q2 | 266.5 Million EUR | 0.0% |
| 2013 Q1 | 292.5 Million EUR | 0.0% |
| 2013 Q2 | 292.5 Million EUR | 0.0% |
| 2013 Q3 | 266.5 Million EUR | -8.89% |
| 2013 Q4 | 266.5 Million EUR | 0.0% |
| 2013 FY | - EUR | 3.55% |
| 2012 FY | - EUR | 20.35% |
| 2011 FY | - EUR | 5.28% |
| 2010 FY | - EUR | 9.13% |
| 2009 FY | - EUR | 14.93% |
| 2008 FY | - EUR | 2.43% |
| 2007 FY | - EUR | 11.02% |
| 2006 FY | - EUR | 12.37% |
| 2005 FY | - EUR | -1.86% |
| 2004 FY | - EUR | 7.44% |
| 2003 FY | - EUR | 2.8% |
| 2002 FY | - EUR | 9.54% |
| 2001 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 641209.431% |
| Ansell Limited | 209.86 Million USD | -2844.802% |
| Ansell Limited | 206.3 Million USD | -2895.637% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | -14325.837% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 380419.16% |
| Psykey, Inc. | -1.29 Million USD | 477208.077% |
| ConvaTec Group Plc | 455.5 Million USD | -1256.751% |
| ConvaTec Group Plc | 455.5 Million USD | -1256.751% |
| Encision Inc. | -544.19 Thousand USD | 1135722.341% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 4358043.728% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 5621859.301% |
| Innovative MedTech Inc. | -7.67 Million USD | 80633.586% |
| LifePoint, Inc. | -14.2 Million USD | 43614.578% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 99986.86% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 1901638.462% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 2871393.569% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 1523077.742% |
| SmileDirectClub, Inc. | -186.13 Million USD | 3420.099% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | -1280.005% |
| SheerVision, Inc. | -110.53 Thousand USD | 5591291.611% |
| United Health Products, Inc. | -2.5 Million USD | 247081.273% |
| Vasamed, Inc. | -4.57 Million USD | 135198.445% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 273462.303% |
| Yubo International Biotech Limited | -1.17 Million USD | 524857.873% |